Unicycive Therapeutics Inc
NASDAQ:UNCY

Watchlist Manager
Unicycive Therapeutics Inc Logo
Unicycive Therapeutics Inc
NASDAQ:UNCY
Watchlist
Price: 5.56 USD 0.72%
Market Cap: 119.5m USD

Unicycive Therapeutics Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Unicycive Therapeutics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Unicycive Therapeutics Inc
NASDAQ:UNCY
Operating Income
-$32.1m
CAGR 3-Years
-53%
CAGR 5-Years
-75%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Unicycive Therapeutics Inc
Glance View

Market Cap
115.9m USD
Industry
Biotechnology

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 9 full-time employees. The company went IPO on 2021-06-17. The firm is focused on identifying medical conditions within and outside of kidney disease. Its development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb was initially developed by, and licensed from, Spectrum Pharmaceuticals. UNI 494 was initially developed by, and licensed from Sphaera Pharmaceuticals, respectively.

UNCY Intrinsic Value
Not Available

See Also

What is Unicycive Therapeutics Inc's Operating Income?
Operating Income
-32.1m USD

Based on the financial report for Dec 31, 2024, Unicycive Therapeutics Inc's Operating Income amounts to -32.1m USD.

What is Unicycive Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-75%

Over the last year, the Operating Income growth was -55%. The average annual Operating Income growth rates for Unicycive Therapeutics Inc have been -53% over the past three years , -75% over the past five years .

Back to Top